CAR-T Therapies for Aggressive Large Cell Lymphoma Age ≥ 18 Yrs

2nd line CAR Therapies

Expanded Access protocols for commercial CAR-T products manufactured of specification

CCT5028 Phase II Liso-cabtagene Maraleucel (JCAR017) in 2nd Line Therapy in Adult Aggressive B-cell NHL
Pl: Parveen Sponsor: Juno Therapeutics

CCT5044 Phase II/III trial of Bi-cistronic αCD19 & α-20 Cd28 CAR-T in Relapsed/Refractory Large B-Cell Lymphoma
Pl: Gupta Sponsor: JDN Therapeutics

CCT5018 Phase II/III Axicabtagene Ciloleucel in Combo w/ Utomilumab in Refractory Large B-Cell Lymphoma
Pl: Parveen Sponsor: Pending

CCT5036 Phase II Axicabtagene Ciloleucel +/- Rituximab or Lenalidomide in Refractory Large B-Cell Lymphoma
Pl: Parveen Sponsor: Pending

CCT5032 Phase II Anti-CD20 & Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pl: Milos Sponsor: Pending

CCT5042 Phase II Anti-CD20 & Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed/Refractory DLBCL
Pl: Milos Sponsor: Pending

CCT5029 Phase I/II Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Pl: Muffy Stanford

CCT5024 Phase I/II ALLO-501 (AntiCD19 Allogeneic CAR TCell Tx) in Relapsed/Refractory LargeB-Cell & Follicular Lymphoma
Pl: Milos Allogene

CCT5035 Phase 1/2a PBCAR20A in Relapsed/Refractory (R/R) NHL or R/R CLL or Small Lymphocytic Lymphoma
Pl: Gupta Sponsor: Juno Therapeutics

CCT5006 Expanded Access Axicabtagene Ciloleucel in Tx Relapsed/Refractory T-plant- ineligible Aggressive NHL
Pl: Milos Sponsor: Kite

CCT5016 Managed Access Program (MAP) CTL019 in ALL or DLBCL
Pl: Milos Sponsor: Novartis

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Extension Study
- Immunotherapy
- Observation Study
- Enrollment on Hold